Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness: A Retrospective Multi-institutional Cohort Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06292052

Enrollment

209

Registered

2024-03-04

Start date

2017-01-01

Completion date

2024-04-01

Last updated

2024-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.

Interventions

DRUGImmunotherapy

Received neoadjuvant chemotherapy plus immunotherapy

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

* pathologically-confirmed diagnosis of NSCLC by pretreatment biopsy * clinically staged as T1-4N0-2M0 * having undergo neoadjuvant chemoimmunotherapy * the agents of immune checkpoint inhibitors (ICIs) belong to PD-1/L1 inhibitors * having undergo surgery with lymph nodes (LNs) dissection * having postoperative pathology reports with evaluation of primary tumor and LNs response * having accessible pretreatment and preoperative radiology examinations imaging or reports

Exclusion criteria

* using PD-1/L1 inhibitors in the phase of clinical trials * the agents of neoadjuvant therapy including angiogenesis inhibitors * having undergone radiotherapy to treat primary tumor or metastatic LNs before surgery

Design outcomes

Primary

Measure	Time frame	Description
Complete pathologic response	through study completion, an average of 3 months	Tumors with 0% viable tumor cells

Secondary

Measure	Time frame	Description
Major pathologic response	through study completion, an average of 3 months	Tumors with ≤10% viable tumor cells
Complete pathologic response in lymph nodes	through study completion, an average of 3 months	Tumors with 0% viable tumor cells in lymph nodes

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026